as 03-28-2025 4:00pm EST
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Founded: | 1995 | Country: | United States |
Employees: | N/A | City: | HAYWARD |
Market Cap: | 339.8M | IPO Year: | N/A |
Target Price: | $24.43 | AVG Volume (30 days): | 54.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.94 | EPS Growth: | N/A |
52 Week Low/High: | $4.75 - $16.90 | Next Earning Date: | 05-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BNTC Breaking Stock News: Dive into BNTC Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
GlobeNewswire
3 days ago
GlobeNewswire
10 days ago
Zacks
16 days ago
Simply Wall St.
19 days ago
GlobeNewswire
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.